共 50 条
- [41] Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trialLANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (07): : 494 - 500Welzel, Tania M.Asselah, TarikDumas, Emily O.Zeuzem, StefanShaw, DavidHazzan, RawiForns, XavierPilot-Matias, TamiLu, WenjingCohen, Daniel E.Feld, Jordan J.
- [42] Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trialsLANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (11): : 805 - 813Gane, Edward J.Pianko, StephenRoberts, Stuart K.Thompson, Alexander J.Zeuzem, StefanZuckerman, EliBen-Ari, ZivFoster, Graham R.Agarwal, KoshLaursen, Alex L.Gerstoft, JanGao, WeiHuang, Hsueh-ChengFitzgerald, BrianFernsler, DoreenLi, Jerry J.Grandhi, AnjanaLiu, HongSu, Feng-HsiuWan, ShuyanZeng, ZhenChen, Huei-LingDutko, Frank J.Nguyen, Bach-Yen T.Wahl, JaniceRobertson, Michael N.Barr, EliavYeh, Wendy W.Plank, Rebeca M.Butterton, Joan R.Esteban, Rafael
- [43] Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trialLANCET GASTROENTEROLOGY & HEPATOLOGY, 2016, 1 (01): : 36 - 44Waked, ImamShiha, GamalQaqish, Roula B.Esmat, GamalYosry, AymanHassany, MohamedSoliman, RehamMohey, Mohammad A.Allam, NaglaaZayed, NaglaaAsselah, TarikHall, ColeenRedman, RebeccaMobashery, NiloufarDoss, Wahid
- [44] An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated SubstitutionsJOURNAL OF INFECTIOUS DISEASES, 2019, 220 (04): : 557 - 566Huang, Chung-FengHung, Chao-HungCheng, Pin-NanBair, Ming-JongHuang, Yi-HsiangKao, Jia-HorngHsu, Shih-JerLee, Pei-LunChen, Jyh-JouChien, Rong-NanPeng, Cheng-YuanLin, Chun-YenHsieh, Tsai-YuanCheng, Chun-HanDai, Chia-YenHuang, Jee-FuChuang, Wan-LongYu, Ming-Lung
- [45] Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial (vol 1, pg 36, 2016)LANCET GASTROENTEROLOGY & HEPATOLOGY, 2016, 1 (01): : E1 - E1Waked, IShiha, G.Qaqish, R. B.
- [46] Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studiesJOURNAL OF HEPATOLOGY, 2019, 70 (01) : E251 - E251Zuckerman, EliGutierrez, JulioUstianowski, AndrewNaggie, SusannaCaruntu, Florin AlexandruRavendhran, NatarajanSigal, SamuelBarrett, LisaCohen, StanleyCrown, EricDylla, DougFredrick, LindaWang, StanleyPorcalla, ArielMensa, FedericoBruno, Savino
- [47] EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR TREATMENT FOR 8 WEEKS IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS: ANALYSIS OF DATA POOLED FROM PHASE 2 AND 3 STUDIESGASTROENTEROLOGY, 2019, 156 (06) : S1218 - S1218Gutierrez, JulioZuckerman, EliUstianowski, AndrewNaggie, SusannaCaruntu, FlorinRavendhran, NatarajanSigal, SamuelBarrett, LisaCohen, Stanley M.Crown, EricDylla, DougFredrick, LindaWang, StanleyPorcalla, Ariel R.Mensa, FedericoBruno, Savino
- [48] An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resitance-associated substitutionJOURNAL OF HEPATOLOGY, 2019, 70 (01) : E248 - E249Yu, Ming-LungHung, Chao-HungCheng, Pin-NanBair, Ming-JongHuang, Yi-HsiangKao, Jia-HorngShu, Shih-JerLee, Pei-LunChen, Jyh-JouChien, Rong-NanPeng, Cheng-YuanLin, Chun-YenHsieh, Tsai-YuanDai, Chia-YenHuang, Jee-FuHuang, Chung-FengChuang, Wan-Long
- [49] Safety and efficacy of anti-pre-S1 domain monoclonal antibody (HH-003) treatment in patients with co-infection of chronic hepatitis B virus (HBV) and hepatitis D virus (HDV): a single center, open-label, phase 2 trialJOURNAL OF HEPATOLOGY, 2023, 78 : S117 - S117Wang, XinruiChi, XiumeiZhang, YingyuGu, YumeiXiao, LongQi, YongheZou, LiangfengWen, JiayingZhang, YinChen, PanLei, CongYe, BinSui, JianhuaLi, WenhuiNiu, Junqi
- [50] Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trialLANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (12): : 877 - 889Bazinet, MichelPantea, VictorCebotarescu, ValentinCojuhari, LiliaJimbei, PavlinaAlbrecht, JeffreySchmid, PeterLe Gal, FredericGordien, EmmanuelKrawczyk, AdalbertMijocevic, HrvojeKarimzadeh, HadiRoggendorf, MichaelVaillant, Andrew